logo-loader
Cellmid Limited

Cellmid director shows faith in life sciences company through on-market trades

Bruce Gordon has acquired two batches of shares recently with a total value of almost $13,300.

Australian currency
The company has lead programs in multiple disease indications

Cellmid Limited (ASX:CDY) non-executive director Bruce Gordon continues to demonstrate his confidence in the life sciences company through on-market share purchases.

Gordon has acquired a further 8,684 shares valued at almost $3,300 and now holds 110,000 shares in an indirect interest.

Last week’s acquisition follows a recent purchase of more than 26,000 shares valued at $10,000.

READ: Cellmid gains new substantial shareholder as director increases his interest to 6.4%

Other company directors have also been acquiring shares recently in a variety of ways, including on-market trades and participation in the recent share placement and share purchase plan.
US-based non-executive director Dennis Eck is a substantial shareholder with a 6.4% interest after acquiring a further batch of shares valued at $1 million.

Managing director and CEO Maria Halasz acquired shares valued at $100,000 while non-executive director Dr Martin Cross has made purchases valued at $50,400.

READ: Cellmid driving towards profitability with anti-ageing product range

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. 

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

Quick facts: Cellmid Limited

Price: $0.22

Market: ASX
Market Cap: $18.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited (ASX:CDY) chief executive officer and managing director Maria Halasz updates Proactive Investors on the company’s key components for its FY2020 growth strategy, which includes an exciting new global product to assist ageing hair.  Cellmid is a listed company with health...

on 14/8/19

2 min read